Compare ROMA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | AQST |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.0M | 529.4M |
| IPO Year | 2022 | 2007 |
| Metric | ROMA | AQST |
|---|---|---|
| Price | $8.98 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 3.0K | ★ 3.4M |
| Earning Date | 12-23-2025 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $1.16 | $2.94 |
| 52 Week High | $11.77 | $7.55 |
| Indicator | ROMA | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 55.64 |
| Support Level | $8.01 | $4.03 |
| Resistance Level | $9.75 | $5.10 |
| Average True Range (ATR) | 0.35 | 0.26 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 74.59 | 48.53 |
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.